Literature DB >> 18520322

Audiovestibular manifestations in patients with limited systemic sclerosis and centromere protein-B (CENP-B) antibodies.

Juan C Amor-Dorado1, Maria C Arias-Nuñez, Jose A Miranda-Filloy, Carlos Gonzalez-Juanatey, Javier Llorca, Miguel A Gonzalez-Gay.   

Abstract

Audiovestibular dysfunction has been reported in patients with connective tissue disease. Systemic sclerosis (SSc; scleroderma) is a rare connective tissue disease of unknown etiology. In the current study we assess whether audiovestibular involvement is present in patients with limited scleroderma (lSSc). To answer this question we studied a series of 35 consecutive patients who fulfilled well-established classification criteria for lSSc and had antibodies against the major centromere protein-B (CENP-B), and 59 matched controls. Individuals with a history of cerebrovascular complications, syphilis, Ménière and other vestibular syndromes, infections involving the inner ear, barotrauma, or in treatment with ototoxic drugs were excluded. The majority of patients with lSSc were women (94%). The mean age at time of study was 64.5 years, and the mean age at time of disease diagnosis was 56.9 years. Besides Raynaud phenomenon, most patients with lSSc had other typical features of CREST (calcinosis, Raynaud phenomenon, esophageal hypomotility, sclerodactyly, and telangiectasia) syndrome. Twenty-seven (77%) patients showed abnormal hearing loss in the audiogram compared with only 15 (26%) of the controls (p < 0.001). Values of audiometric tests (pure-tone average and speech reception threshold) yielded significant differences between patients and controls (p < 0.001). The typical pattern of hearing impairment in our series of lSSc patients was a bilateral and symmetrical sensorineural hearing loss with a flat pattern in the audiogram. Abnormal tympanogram and abnormal stapedial reflex were more commonly observed in patients than controls (p < or = 0.001). Similarly, a significantly increased frequency of abnormal oculocephalic response (10 patients, 29%) and head-shaking nystagmus (9 patients, 26%) was observed in patients compared with controls (p < 0.001 for both comparisons). Finally, a significantly increased frequency of abnormal caloric test and clinical test of sensory integration and balance was observed in lSSc patients (31% and 46% of patients, respectively) compared with controls (0% and 12%, respectively) (p < 0.001 for both comparisons). The current study demonstrates strong evidence for inner ear compromise in patients with lSSc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18520322     DOI: 10.1097/MD.0b013e318173aa56

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  5 in total

1.  Reliability of the nanopheres-DNA immunization technology to produce polyclonal antibodies directed against human neogenic proteins.

Authors:  Ahmed Arnaoty; Valérie Gouilleux-Gruart; Sophie Casteret; Bruno Pitard; Yves Bigot; Thierry Lecomte
Journal:  Mol Genet Genomics       Date:  2013-06-07       Impact factor: 3.291

2.  Hearing organ disorders in patients with systemic sclerosis.

Authors:  Katarzyna Maciaszczyk; Elżbieta Waszczykowska; Anna Pajor; Bożena Bartkowiak-Dziankowska; Tomasz Durko
Journal:  Rheumatol Int       Date:  2010-05-12       Impact factor: 2.631

3.  Hearing Loss Secondary to Systemic Sclerosis Vasculopathy: Case Study with a Short Review.

Authors:  Carmen Bobeica; Elena-Laura Parapiru; Carmina Liana Musat; Ciprian Dinu; Iulia Chiscop; Luiza Nechita; Victorita Stefanescu; Ioana Anca Stefanopol; Ana Maria Pelin; Alexandru Nechifor; Gabriela Balan; Elena Niculet; Mihaela Craescu; Alin Laurentiu Tatu
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-05-30

4.  The impact of ankylosing spondylitis on audiovestibular functions.

Authors:  Zeliha Kapusuz Gencer; Mahmut Özkırış; Ilhan Günaydın; Levent Saydam
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-06       Impact factor: 2.503

5.  Hearing loss in patients with scleroderma: associations with clinical manifestations and capillaroscopy.

Authors:  S Shenavandeh; S B Hashemi; MahmoodReza Masoudi; M A Nazarinia; A Zare
Journal:  Clin Rheumatol       Date:  2018-06-02       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.